Skip to main content
. Author manuscript; available in PMC: 2023 Jan 26.
Published in final edited form as: J Am Geriatr Soc. 2022 Nov 8;71(2):414–422. doi: 10.1111/jgs.18116

Figure 2. Antipsychotic, antianxiety, antidepressant, hypnotic, and opioid use among Michigan long-stay nursing home residents with Alzheimer’s disease and related dementias (ADRD), January 1, 2018 – June 30, 2021a.

Figure 2.

a The percentage of monthly medication use (i.e., antidepressant, opioid, antianxiety, antipsychotic, and hypnotic) use was examined on all Minimum Data Set assessments per resident for a given month. Opioid medication use measurement started in March 2018. Residents with Huntington’s disease, Tourette syndrome, and schizophrenia were excluded. Enlargement portrays the monthly percentage of antidepressant, opioid, antianxiety, and antipsychotic medication use during COVID-19 among long-stay nursing home residents with ADRD.